Savant Capital LLC Grows Stock Position in Incyte Co. (NASDAQ:INCY)

Savant Capital LLC raised its position in shares of Incyte Co. (NASDAQ:INCY - Free Report) by 304.8% in the fourth quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The firm owned 52,792 shares of the biopharmaceutical company's stock after purchasing an additional 39,749 shares during the quarter. Savant Capital LLC's holdings in Incyte were worth $3,646,000 as of its most recent SEC filing.

A number of other large investors have also made changes to their positions in the company. Orion Portfolio Solutions LLC bought a new position in shares of Incyte during the 3rd quarter valued at approximately $770,000. CWA Asset Management Group LLC bought a new position in shares of Incyte during the 4th quarter valued at approximately $1,933,000. Greenwood Capital Associates LLC bought a new position in shares of Incyte during the 3rd quarter valued at approximately $433,000. Tri Ri Asset Management Corp bought a new position in shares of Incyte during the 3rd quarter valued at approximately $3,292,000. Finally, Cypress Capital Group bought a new position in shares of Incyte during the 3rd quarter valued at approximately $971,000. 96.97% of the stock is currently owned by institutional investors.

Insider Buying and Selling at Incyte

In other news, insider Thomas Tray sold 650 shares of the stock in a transaction on Monday, December 16th. The stock was sold at an average price of $69.31, for a total transaction of $45,051.50. Following the transaction, the insider now owns 23,312 shares of the company's stock, valued at approximately $1,615,754.72. This represents a 2.71 % decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this link. Also, EVP Vijay K. Iyengar sold 6,043 shares of the stock in a transaction on Friday, November 29th. The stock was sold at an average price of $75.38, for a total value of $455,521.34. Following the transaction, the executive vice president now directly owns 30,658 shares in the company, valued at $2,311,000.04. The trade was a 16.47 % decrease in their position. The disclosure for this sale can be found here. Insiders have sold 19,695 shares of company stock valued at $1,444,356 in the last quarter. 17.60% of the stock is owned by insiders.

Incyte Trading Up 0.6 %

NASDAQ:INCY traded up $0.41 during midday trading on Friday, hitting $70.42. 1,882,071 shares of the company traded hands, compared to its average volume of 1,255,658. The firm's fifty day moving average is $71.26 and its 200-day moving average is $69.18. Incyte Co. has a 12-month low of $50.35 and a 12-month high of $83.95. The firm has a market capitalization of $13.63 billion, a P/E ratio of 503.04, a P/E/G ratio of 0.53 and a beta of 0.70. The company has a current ratio of 1.87, a quick ratio of 1.82 and a debt-to-equity ratio of 0.01.

Incyte (NASDAQ:INCY - Get Free Report) last announced its quarterly earnings data on Monday, February 10th. The biopharmaceutical company reported $1.09 EPS for the quarter, missing the consensus estimate of $1.57 by ($0.48). Incyte had a net margin of 0.80% and a negative return on equity of 0.63%. On average, sell-side analysts predict that Incyte Co. will post 0.35 EPS for the current year.

Analysts Set New Price Targets

INCY has been the topic of a number of research analyst reports. Bank of America raised Incyte from a "neutral" rating to a "buy" rating and boosted their price target for the stock from $68.00 to $90.00 in a report on Tuesday, October 29th. Cantor Fitzgerald reissued a "neutral" rating on shares of Incyte in a report on Friday, January 10th. Morgan Stanley boosted their price target on Incyte from $64.00 to $69.00 and gave the stock an "equal weight" rating in a report on Wednesday, October 30th. Oppenheimer boosted their price target on Incyte from $81.00 to $82.00 and gave the stock an "outperform" rating in a report on Wednesday, October 30th. Finally, Citigroup lowered their price target on Incyte from $97.00 to $88.00 and set a "buy" rating on the stock in a report on Tuesday. One investment analyst has rated the stock with a sell rating, eleven have given a hold rating and nine have issued a buy rating to the company's stock. Based on data from MarketBeat, the stock has a consensus rating of "Hold" and an average target price of $75.59.

About Incyte

Incyte Corporation, a biopharmaceutical company, engages in the discovery, development, and commercialization of therapeutics for hematology/oncology, and inflammation and autoimmunity areas in the United States and internationally. The company offers JAKAFI (ruxolitinib) for treatment of intermediate or high-risk myelofibrosis, polycythemia vera, and steroid-refractory acute graft-versus-host disease; MONJUVI (tafasitamab-cxix)/MINJUVI (tafasitamab) for relapsed or refractory diffuse large B-cell lymphoma; PEMAZYRE (pemigatinib), a fibroblast growth factor receptor kinase inhibitor that act as oncogenic drivers in liquid and solid tumor types; ICLUSIG (ponatinib) to treat chronic myeloid leukemia and Philadelphia-chromosome positive acute lymphoblastic leukemia; and ZYNYZ (retifanlimab-dlwr) to treat adults with metastatic or recurrent locally advanced Merkel cell carcinoma, as well as OPZELURA cream for treatment of atopic dermatitis.